Jove
Visualize
联系我们

相关概念视频

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  2. 河马通路缺陷可以逆转心脏梗塞后的心力衰竭
  1. 首页
  2. 河马通路缺陷可以逆转心脏梗塞后的心力衰竭

相关实验视频

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K

河马通路缺陷可以逆转心脏梗塞后的心力衰竭

John P Leach1, Todd Heallen2, Min Zhang1,3

  • 1Department of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.

Nature
|October 5, 2017

在PubMed 上查看摘要

概括
此摘要是机器生成的。

在心力衰竭的小鼠中删除Hippo路径组件Salvador (Salv) 有助于修复. 这包括增加血管性,减少纤维化,改善心脏功能,突出显示之前未知的修复能力.

更多相关视频

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

10.0K

相关实验视频

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.5K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

10.0K

科学领域:

  • 心血管生物学
  • 复原医学
  • 分子心脏病学

背景情况:

  • 哺乳动物的器官具有有限的再生能力, 心脏在受伤后特别容易衰竭.
  • 经常导致死亡的心力衰竭与Hippo通路信号的高调相关,这抑制了成人心肌细胞的增殖.
  • 河马通路作为器官大小和再生的关键调节者.

研究的目的:

  • 在已确定的缺血性心力衰竭的背景下调查Hippo路径,特别是Salvador (Salv) 组成部分的作用.
  • 通过调节Hippo路径可以诱导心肌细胞的修复基因程序并改善心脏功能.
  • 探索基因疗法治疗心力衰竭的潜力.

主要方法:

  • 使用已确诊的心脏衰竭的小鼠模型.
  • 在心肌细胞中删除了Hippo路径组件Salvador (Salv).
  • 使用翻译核糖体亲和度净化来分析心肌细胞特异性信使RNA.
  • 进行基因研究以评估Park2等特定基因在心脏修复中的作用.
  • 使用编码Salv短毛针RNA的病毒进行基因治疗.

主要成果:

  • 在失败的小鼠心脏中删除Salv启动了修复计划,其特点是痕边缘血管性增加和纤维化减少.
  • 缺血性心肌细胞表现出增多性和应激反应基因的表达,包括线粒体质量控制基因Park2.
  • 基因切除Park2导致心脏修复受损,这表明Park2在心肌再生中的重要作用.
  • 用Salv短发针RNA进行基因治疗改善了心脏功能,无论是在心脏病发作期间还是心力衰竭后.
  • 与对照小鼠相比,该研究显示治疗小鼠的功能得到改善.
  • 结论:

    • 河马通路是心肌细胞增殖和再生的关键调节者,其抑制可以促进心脏修复.
    • 通过Park2进行线粒体质量控制对于心肌的再生能力至关重要.
    • 例如,通过用Salv短毛针RNA进行基因疗法, 针对Hippo路径提供了对心力衰竭的有希望的治疗策略.
    • 失败的心脏具有潜在的修复潜力, 通过调节特定的分子通路,